NCT01986998View on ClinicalTrials.gov

Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse

PHASE4CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

March 31, 2016

Conditions
Multiple Sclerosis
Interventions
DRUG

Methylprednisolone 1250 mg/24h x3 days

Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)

DRUG

Oral Methylprednisolone 625 mg/24h x3 days

Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)

Trial Locations (8)

17007

Hospital Universitari de Girona Dr. Josep Trueta, Girona

25198

Hospital Universitari Arnau de Vilanova de Lleida, Lleida

08916

Hospital Universitari Germans Trias I Pujol de, Badalona

08003

Hospital Del Mar, Barcelona

08034

Hospital de Mataró, Barcelona

08036

Hospital Clinic I Provincial de Barcelona, Barcelona

Unknown

Hospital de Sant Joan Despí Moisés Broggi, Barcelona

Hospital de Sant Pau I Santa Tecla, Tarragona

All Listed Sponsors
lead

Germans Trias i Pujol Hospital

OTHER

NCT01986998 - Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse | Biotech Hunter | Biotech Hunter